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Context: Parathyroid carcinoma (PC) is extremely rare. Prognosis is poor, with no known evidence-based
systemic therapies.We previously reported complete remission in a patientwithmetastasized parathyroid
carcinoma and high tumor MGMT promoter methylation status who was treated with temozolomide.
Objective: To study MGMT promoter methylation status in an additional set of aggressive
parathyroid tumors.
Design/Setting: The study included 12 patients: 7 with sporadic and 5 with familial primary hyper-
parathyroidism (two of the latter carried a CDC73 gross deletion). Patient 9 is the previously described
patient with PC and high MGMT methylation status. Her daughter (patient 12) had surgery for severe
primary hyperparathyroidism due to atypical parathyroid adenoma during pregnancy. Eleven patients
thus had PC and one had atypical parathyroid adenoma. MGMT promoter methylation status was
determined fromDNAextracted fromprimary (n5 10) ormetastatic (n5 2) tumors. Ameanmethylation
level .20% was considered high. Patient 11 had metastatic PC and received temozolomide cycles.
Results: Only the previously published patient (patient 9) had high tumor MGMT promoter meth-
ylation status. This was not a characteristic of the atypical parathyroid adenoma of the daughter
(patient 12). Patient 11 (CDC73 intragenic deletion) has disseminated PC, low MGMT promoter
methylation, and stable disease on follow-up after temozolomide treatment.
Conclusion: High MGMT promoter methylation status seems rare in PC. However, as demonstrated
in other neuroendocrine tumors, some patients with disseminated PCmight benefit from temozolomide.
Demonstration of high methylation status could be a predictor of positive response to
temozolomide treatment.
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Parathyroid carcinoma (PC) is an extremely rare malignancy and therefore difficult to di-
agnose. PC cannot be confirmed before surgery because no specific biomarkers are available.
PC underlies 1% of primary hyperparathyroidism (PHPT) cases and should be suspected in
patients with biochemically severe disease, often kidney and bone manifestations [1].
However, there are reports of increasing incidences in Australia, the United States, and
Europe [2–4]. Reported recurrence rates are 20% to 50%, and 5-year survival in patients with
metastatic disease is,50% [5–7]. Radical primary surgery is the only curative treatment and
is the first-line therapy also for recurrent disease.
The prognosis for inoperable disease is especially poor because no effective systemic
therapies have been identified so far. There are some reports of treatment responses to
external radiotherapy and anecdotal case reports of successful response to dacarbazine (an
alkylating agent), sorafenib (a multikinase inhibitor), and immunotherapy with intradermal
injections of synthetic human and bovine PTH peptide fragments [8–12]. Patients with
metastatic PC usually die of severe hypercalcemia and renal insufficiency rather than of the
tumor burden itself [1].
We recently reported a case of recurrent, disseminated PC with complete remission in
response to repeat surgery, temozolomide (TEM), external radiotherapy, cinacalcet, and
bisphosphonates [13]. This patient’s PC demonstrated high O6-methylguanine DNA meth-
yltransferase (MGMT) promoter methylation status. High MGMT promoter methylation is a
known predictor of positive treatment response to TEM in other neuroendocrine tumors, such
as aggressive pituitary tumors [14] and pancreatic neuroendocrine tumors (NETs) [15, 16]. The
MGMT enzyme is a DNA-repairing enzyme that counteracts the DNA-damaging effects of
alkylating agents, such as TEM. Silencing of the MGMT gene by promoter methylation en-
hances the cytotoxic effects of TEM [17]. MGMT promoter methylation status has not been
systematically investigated in PC, except for the one previously reported case [10].
Our aim here was to investigate whether high MGMT promoter methylation status is
common in aggressive parathyroid tumors by studying an additional set of PCs (n 5 11,
including tumor tissue from the previously described patient with PC, patient 9) and one
atypical parathyroid adenoma (this patient with APA is the daughter of the previously
described patient 9) and corresponding patient characteristics and outcomes. We also de-
scribe treatment with TEM, external radiotherapy, cinacalcet, and denosumab in another
patient with metastasized PC, who had an underlying CDC73 mutation and low tumor
MGMT promoter methylation status.
1. Materials and Methods
A. Patient Cohort
The study cohort consists of 12 patients with PC (n 5 11) and 1 patient with atypical
parathyroid adenoma (patient 12), all diagnosed, operated on, and treated at the Department
of Endocrinology, Helsinki University Hospital between 1993 and 2018. The successful
combined treatments of patient 9 (including TEM cycles for 1 year), resulting in complete
remission, have been previously described [13].
Patient data and laboratory results were obtained from the electronic patient record
database at the Helsinki University Hospital in November 2018. Patient 11 was followed
until the end of May 2019. All biochemical measurements were performed with in-house
methods at HUSLAB, the central laboratory of our hospital. The most recent serum ionized
calcium (normal range, 1.16 to 1.3 mmol/L at a pH of 7.4) and fasting plasma PTH (normal
range, 15 to 70 ng/L) concentrations, as well as detailed information on therapies and re-
currences, were retrieved from our electronic patient files. All histopathological character-
istics of the tumors were reviewed by an expert parathyroid pathologist.
TheHelsinki University Hospital Ethics Committee and the Finnish National Supervisory
Authority forWelfare andHealth (Valvira) (Dnro 8031/06.01.03.01/2015) approved the study.
The patients have given their informed consent for participation in this study.
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B. MGMT Promoter Methylation and CDC73 Gene Mutation Status
MGMTpromotermethylation status was determined from formalin-fixed, paraffin-embedded
(FFPE) tumor tissue excised at primary surgery (n 5 10) or from a metastatic lesion (n 5 2,
patients 9 and 11). A mean methylation level .20% of all investigated CpGs was
considered methylated.
Tumor DNA for determination of MGMT promoter methylation status was isolated by
using GeneRead DNA FFPE Kit (Qiagen, Hilden, Germany), optimized for isolation of DNA
from FFPE tissues. The quantity and quality of DNA were assessed by using NanoDrop 8000
Spectrophotometer (ThermoFisher Scientific, Waltham, MA). DNA concentrations were 300
to 1000 ng/mL per sample, and A260/A280 ratios in the range of 1.8 to 2.0 were considered
satisfactory for purity standards. Unmethylated cytosine residues were converted to uracils
by sodium bisulfite treatment of DNA (EpiTect Bisulfite Kit, Qiagen, Hilden, Tyskland),
whereas methylated residues were left unchanged. Methylation of the five CpGs and one
control CpG was analyzed in duplicated reactions by a cyclic minisequencing after PCR [18].
One negative and two positive (high, low) controls were used in each run to confirm successful
PCR and calculate cutoff values for automated genotype calling from 20 previous test runs.
CDC73 mutation status was determined as previously described [2]. None of the patients
had multiple endocrine neoplasia type 1 based on genetic screening and/or the absence of
multiple endocrine neoplasia type 1 manifestations on clinical follow-up. Next-generation
sequencing of a PHPT gene panel (AIRE, AIP, APC, CDC73, CDKN1A, CDKN1B, CDKN2B,
CDKN2C, GCM2, GNA11, MEN1, PTH, andRET) was introduced as a standard procedure in
our clinic in 2016 and thus was performed among the patients diagnosed in 2016 and later
(patients 1 and 2), with negative results.
2. Results
The clinical characteristics of the 12 patients are given in Table 1. Five are female and 7 are
male, and the age at diagnosis ranged from 17 to 76 years. Four patients (patients 6, 8, 9, and
11) have been treated for local recurrent PC or distantmetastases. All patients except patient
11 are in remission at the time of this report (serum ionized calcium, 1.30mmol/L). Patients
4 and 9 through 12 are characterized by familial PHPT. Patient 1 underwent neck exploration
and parathyroidectomy because of tertiary hyperparathyroidism due to focal segmental
glomerulosclerosis and end-stage renal failure. Histopathological diagnosis was parathyroid
carcinoma of the right lower parathyroid, atypical adenoma of the right upper parathyroid,
and hyperplasia of both left parathyroids. Patient 5 was diagnosed with gonadal dysgenesia
(46XY/45X0) at birth. Patient 12 was diagnosed with severe PHPT during pregnancy and is
the daughter of patient 9; her PHPT was due to an atypical parathyroid adenoma (Tables 1
and 2).
Data on familial PHPT, CDC73 gene mutation status, affected parathyroid glands, his-
topathological criteria of PC, and Ki67 and parafibromin staining are given in Table 2. All
tumors except that from patient 9 (the previously published case [13]) had low tumorMGMT
promoter methylation status.
A. Surgery, TEM, and Other Adjuvant Treatments in a Patient With a CDC73 Mutation,
Disseminated PC, and Low MGMT Methylation Status
Patient 11 was diagnosed with severe PHPT due to PC in 1993 at age 32 years. He carries a
CDC73 gross deletion of exons 1 to 10, as previously reported [18]. Parafibromin staining was
negative and Ki67 was 20% (Table 2). He was not cured by primary surgery and has been
operated on several times because of metastases in the neck and in the vicinity of the thoracic
spine. At the end of 2017, his serum ionized calcium (1.45 to 1.69mmol/L) and PTH (786 ng/L)
concentrations again increased. The underlying lesion was difficult to localize, and the
patient underwent planar scintigraphy with 123I 99mTC-sestamibi, 18F-fluorodeoxyglucose
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positron emission tomography and 11C-methionine positron emission tomography/MRI.MRI
confirmed a recurrent metastasis in vertebra C6 (Fig. 1A) and a 3-cm tumor in the right
kidney (Fig. 1B) that proved to be papillary type 1 renal carcinoma. MGMT methylation
status, determined from the metastatic lesion resected in March 2018, was low (Table 2).
The patient was treated with TEM cycles (280 mg for 5 days, with 28-day intervals)
between March and October 2018, cinacalcet, zoledronic acid 4 mg every 4 weeks, and ex-
ternal radiotherapy of the C6 metastatic lesion.
In October 2018, CT demonstrated growth of the C6 metastasis (Fig. 1C) and lung me-
tastases. TEM treatment was subsequently stopped. Zoledronic acid was replaced by
denosumab 120 mg every 4 weeks, and cinacalcet was discontinued inMarch 2019 because of
nausea. In January 2019, thoracic CT demonstrated stable disease, with minor tumor
shrinkage. As of May 2019, the serum ionized calcium was 1.62 mmol/L and creatinine level
was 117 mmol/L. This patient is also the uncle of patient 10, who was diagnosed with severe
PC at age 18 years and carries the same CDC73 gross deletion [18]. This patient had two
abnormal parathyroids and low MGMT promoter methylation of the PC (Table 2).
3. Discussion
We studied MGMT promoter methylation status in aggressive parathyroid tumors from 12
(11 with PC and 1 with atypical parathyroid adenoma) well-characterized patients operated
on for PHPT; this has not previously been done in any series of PC/aggressive parathyroid
tumors before. High MGMT methylation status was found in only one of these tumors
Table 1. Patient Characteristics
Patient
No. Sex
Year of
Primary
Surgery
Age at
Diagnosis
(y)
Ionized
Calcium at
Diagnosis
(mmol/L)
PTH at
Diagnosis
(ng/L)
Current
Ionized
Calcium
(mmol/L)
Current
PTH
(ng/L)
Recurrent
Disease
1 F 2016 25 1.35 2207 1.23 132 No
2 M 2018 76 2.11 2389 1.21 82 No
3 F 2014 49 2.08 576 1.22 75 No
4 M 2008 17 1.76 1187 0.81 16 No
5 M 2004 35 2.58 4000 1.21 93 No
6 M 2009 45 1.88 358 1.18 56 Local recurrence
2012,
reoperation 1
left lobectomy
7 F 2010 61 2.71 3300 1.21 60 No
8 M 2007 42 1.5 178 1.19 97 Recurrent PHPT
in 2014,
reoperation:
left lower
parathyroid:
hyperplasia or
adenoma
9 F 2001 48 2.16 2020 1.05 31 Previously
published:
recurrent,
disseminated
disease
10 M 2011 18 1.88 693 1.15 108 No
11 M 1993 32 3.96
(total serum
calcium)
1830 1.62 450 Persistent,
disseminated
disease
12 F 2008 33 1.96 823 1.19 91 No
Abbreviations: F, female; M, male.
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(patient 9), as previously described [10]. High MGMT promoter methylation is a known
predictor of positive treatment response to TEM in other NETs, such as aggressive pituitary
tumors and pancreatic NETs [14–16].
All parathyroid tumors underwent careful histopathological examination by our expert
parathyroid pathologist. In addition, all patients are under regular follow-up and have been
treated accordingly for possible recurrent PHPT in our institution. In patient 1, PCmay have
been driven by proliferation of parathyroid cells due to tertiary hyperparathyroidism and
underlying end-stage renal failure, as describe by Miki et al [19]. We wanted to include both
familial and sporadic cases of PC to explore whether these factors could be related toMGMT
promoter methylation status. Some of the familial cases may represent phenocopies. For
patient 9, who had PC and high MGMT methylation status, and her daughter (patient 12),
the underlying gene defect has not been identified. For instance, possible GCM2 mutations
have not been ruled out. MGMT methylation was also low in the atypical adenoma of the
daughter, revealing distinct methylation reprogramming ofMGMT promoter in the tumor of
this first-degree relative. According to the current study, the MGMT gene promoter is thus
supposedly not regularlymethylated in aggressive parathyroid tumors. However, because PC
is very rare, only 12 patients/tumors were included in the present series. It is difficult to
gather a large enough PC cohort for more comprehensive analyses. Considering the prev-
alence of PC, our patient cohort is of reasonable size.
There are different methods of assessing MGMT methylation status. Although immu-
nohistochemistry is the simplest and cheapest method, it does not correlate well with other
methods or with clinical treatment response to alkylating agents [20]. Bisulfite treatment
methylation-specific PCR, as used in our study, is considered the gold standard because it
gives quantitative information on MGMT methylation status [21]. It is, however, possibly
associated with inaccurate results because only a few CpGmethylation sites are analyzed. In
addition, promoter methylation status of tumors with variable methylation status of specific
CpG sitesmight be falsely considered low [20].With the cyclingminisequencingmethod used,
false results have been minimized by using duplicate reactions, controls, and follow-up of
results from previous runs. Because different PCR assays can yield different results, the
specificity and sensitivity depend on themethod used. For the current study it depends on the
PCR protocol [22].
Figure 1. (A) 1.5-T axial plane T2-weighted MRI demonstrating a metastatic soft tissue
mass in the left anterolateral cortex of C6 (straight arrow). (B) Contrast-enhanced CT scan in
coronal plane of the right kidney shows multiple cortical cysts and a solid tumor mass
(arrowheads). (C) Contrast-enhanced CT scan in axial plane reveals marked growth of the C6
metastatic mass, which has caused a large lytic cortical lesion (curved arrow).
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Methylation-specific PCR, with its high sensitivity, is widely used for assessing MGMT
methylation in the research setting but suffers from increased false-positivity. Pyrose-
quencing is considered the most accurate and robust method for determining MGMT
methylation status [23, 24]. With FFPEDNA, there is a risk of false-positive or false-negative
results, especially when the DNA quality and/or quantity is low [25]. We tried to avoid
inaccurate results by isolating DNAwith amethod designed for FFPEmaterial and used only
specimens with good DNA concentrations and satisfactory purity (260/280 1.8 to 2.0).
The MGMT gene is epigenetically inactivated by promoter hypermethylation in ;40% of
primary glioblastomas [26], in whichMGMTmethylation is associated with improved overall
survival [27]. Owen et al. [28] studied MGMT expression in gastroenteropancreatic NETs as
well as in NETs originating from the lung and thymus. At 2 years, patients with low MGMT
protein expression on immunohistochemistry receiving capecitabine and TEM treatment had
better outcomes than patients with higher MGMT protein expression. However, there were
also patients in the high MGMT expression group who responded to treatment (i.e., reached
partial remission or stable disease) [28]. Some studies did not show different treatment
response to TEM according to MGMT status [29]. It is thus possible, as in patient 11 of the
current study, that partial response or stable disease can be achieved with TEM in some
patients with PC regardless of MGMT status, as previously demonstrated in other NETs.
However, further studies are needed to clarify this.
Because PC is very rare, treatment of patients with recurrent PC could benefit from de-
velopments in personalized cancer care in the future. Some suggested treatment targets in-
clude different inhibitors of the PIK3CA-PTEN-mTOR-AKT pathway, such as sorafenib and
everolimus [12, 30, 31]. For patientswith recurrent PC, efficient treatment therapies are scarce
and thus urgently needed. Demonstration of highMGMTmethylation status could thus serve
as a predictor of positive treatment response to TEM and tailoring of the treatment.
4. Conclusion
We recommendMGMT promoter methylation testing in recurrent PC not curable by surgery
because high methylation status could indicate good treatment response to TEM. Some
treatment response may be achieved regardless of MGMT methylation status.
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